Office of Research New Faculty Orientation will take place on Friday, September 6, 2024 from 8:00am to 11:00am in Diboll Gallery and Auditorium, 1440 Canal Street, Tidewater Bldg. Click here for the New Faculty Orientation website.

Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed)

1 month 1 week ago
Funding Opportunity RFA-DA-25-040 from the NIH Guide for Grants and Contracts. The purpose of this concept is to facilitate the formation and maintenance of multidisciplinary research teams ready to employ epidemiological and/or etiological datasets and analyses to answer substance use prevention research questions and apply findings to intervention development or implementation. Projects supported through this concept will combine hands-on meeting formats, including both sandpit and hackathon approaches, with activities to sustain new research teams and networks, creating a foundational structure for research programs that have impact across disciplines.

Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)

1 month 1 week ago
Funding Opportunity RFA-NS-25-013 from the NIH Guide for Grants and Contracts. Applications to this NOFO will propose research to establish clinical trial readiness for community-driven interventions to understand and develop solutions addressing barriers to equity in ADRD outcomes among populations defined by the NIH to experience health disparities and communities that intersect with them. Applications should consider the social, ethical, and behavioral implications (SEBI) related to assessing risk for, identification of, or treatment of ADRD among underserved and marginalized populations and how these factors may relate to existing or potential barriers to achieving equity and impact future clinical trials.

Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional)

1 month 1 week ago
Funding Opportunity RFA-CA-24-027 from the NIH Guide for Grants and Contracts. Through this Funding Opportunity Announcement (FOA), the NCI intends to support multi-level intervention studies that address individual and system level barriers to transition from pediatric to adult care for survivors of childhood and adolescent cancers. The goal of this opportunity is to support the development and testing of interventions and strategies that promote high-quality transitional care and continued engagement of survivors of childhood and adolescent cancers to ensure these survivors receive appropriate surveillance and care into adulthood. Overall, it is anticipated that this research will provide critical evidence for establishing best practices and standards of care that can be widely disseminated and adopted.

CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)

1 month 1 week ago
Funding Opportunity RFA-ES-24-005 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the eyes and lungs. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).

Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional)

1 month 1 week ago
Funding Opportunity RFA-HD-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites new applications for Centers for Collaborative Research in Fragile X andFMR1-Associated Conditions (hereafter termed "Fragile X Centers"). Despite many remarkable advances in fundamental knowledge about FMR1-associated conditions, gaps in knowledge remain about the processes that drive the variability in clinical features (phenotypic heterogeneity) among affected individuals. In this round of competition, therefore, all centers will be required to identify an overarching theme directed at broadening our understanding of factors underlying the phenotypic heterogeneity and/or variability in response to interventions seen in one or more FMR1 associated conditions. Successful Fragile X Centers will be composed of multidisciplinary teams of basic, translational, clinical, and/or data science investigators applying precision medicine approaches (seeking to understand which mechanisms and interventions are most applicable to specific individuals or groups) to address the center's proposed overarching theme. This NOFO includes specific requirements about inclusion of research on human subjects or human phenotypic data; diversity of participants or materials being studied; the types of allowable clinical trials; and involvement of early-stage investigators. Applications that do not adhere to these requirements will be considered nonresponsive to this NOFO and will be withdrawn. In addition, this NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.Applicants are strongly encouraged to read the NOFO instructions carefully and view the availablePEDP guidance material.

HEAL Initiative: JCOIN Phase II Innovation Hubs (R01 Clinical Trial Optional)

1 month 1 week ago
Funding Opportunity RFA-DA-25-062 from the NIH Guide for Grants and Contracts. Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if they have not received MOUD while detained. Most US jails do not offer MOUD to everyone who could benefit from them. JCOIN focuses on the translation of research-to-practice to address the overdose crisis in the context of the criminal justice system specifically, increasing delivery of and access to MOUD. A portfolio of research projects conducts hybrid effectiveness-implementation trials to address key barriers to delivery of evidence-based OUD treatments to justice-involved populations. This is the only HEAL initiative with a primary focus on justice-involved populations and criminal-legal systems.

HEAL Initiative: JCOIN Phase II Economic Research Resource Center (U24 Clinical Trial Optional)

1 month 1 week ago
Funding Opportunity RFA-DA-25-061 from the NIH Guide for Grants and Contracts. Individuals in the US justice system are disproportionately likely to have SUD/OUD, are at high risk for opioid withdrawal upon incarceration, and are at elevated risk for overdose post-release if they have not received MOUD while detained. Most US jails do not offer MOUD to everyone who could benefit from them. JCOIN focuses on the translation of research-to-practice to address the overdose crisis in the context of the criminal justice system specifically, increasing delivery of and access to MOUD. A portfolio of research projects conducts hybrid effectiveness-implementation trials to address key barriers to delivery of evidence-based OUD treatments to justice-involved populations. This is the only HEAL initiative with a primary focus on justice-involved populations and criminal-legal systems.
Checked
15 hours 8 minutes ago
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Subscribe to NIH Grants feed